Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia | Zendy

Pierre Sujobert | Zendy; Laury Poulain | Zendy; Étienne Paubelle | Zendy; Florence Zylbersztejn | Zendy; Adrien Grenier | Zendy; Mireille Lambert | Zendy; Elizabeth C. Townsend | Zendy; JeanMarie Brusq | Zendy; Edwige Nicodème | Zendy; Justine Decrooqc | Zendy; Iepstad | Zendy; Alexa S. Green | Zendy; Johanna Mondésir | Zendy; MarieAnne Hospital | Zendy; Nathalie Jacque | Zendy; Alexandra Christodoulou | Zendy; Tiffany DeSouza | Zendy; Olivier Hermine | Zendy; Marc Foretz | Zendy; Benoı̂t Viollet | Zendy; Catherine Lacombe | Zendy; Patrick Mayeux | Zendy; David M. Weinstock | Zendy; Ivan Cruz Moura | Zendy; Didier Bouscary | Zendy; Jérôme Tamburini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia

Author(s) -

Pierre Sujobert,

Laury Poulain,

Étienne Paubelle,

Florence Zylbersztejn,

Adrien Grenier,

Mireille Lambert,

Elizabeth C. Townsend,

JeanMarie Brusq,

Edwige Nicodème,

Justine Decrooqc,

Iepstad,

Alexa S. Green,

Johanna Mondésir,

MarieAnne Hospital,

Nathalie Jacque,

Alexandra Christodoulou,

Tiffany DeSouza,

Olivier Hermine,

Marc Foretz,

Benoı̂t Viollet,

Catherine Lacombe,

Patrick Mayeux,

David M. Weinstock,

Ivan Cruz Moura,

Didier Bouscary,

Jérôme Tamburini

Publication year - 2015

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2015.04.063

Subject(s) - mtorc1 , ampk , cancer research , myeloid leukemia , haematopoiesis , myeloid , microbiology and biotechnology , protein kinase b , biology , signal transduction , chemistry , stem cell , phosphorylation , protein kinase a

AMPK is a master regulator of cellular metabolism that exerts either oncogenic or tumor suppressor activity depending on context. Here, we report that the specific AMPK agonist GSK621 selectively kills acute myeloid leukemia (AML) cells but spares normal hematopoietic progenitors. This differential sensitivity results from a unique synthetic lethal interaction involving concurrent activation of AMPK and mTORC1. Strikingly, the lethality of GSK621 in primary AML cells and AML cell lines is abrogated by chemical or genetic ablation of mTORC1 signaling. The same synthetic lethality between AMPK and mTORC1 activation is established in CD34-positive hematopoietic progenitors by constitutive activation of AKT or enhanced in AML cells by deletion of TSC2. Finally, cytotoxicity in AML cells from GSK621 involves the eIF2α/ATF4 signaling pathway that specifically results from mTORC1 activation. AMPK activation may represent a therapeutic opportunity in mTORC1-overactivated cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research